Moderna, the Healthcare sector company, was revisited by a Wall Street analyst on August 1. Analyst Tim Anderson from Bank of America Securities reiterated a Sell rating on the stock and has a $25.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Sell rating due to a combination of factors impacting Moderna’s financial outlook. The company’s recent quarterly performance showed a decline in stock value, underperforming compared to its larger biopharmaceutical peers. Despite some positive updates on vaccine developments, such as the CMV vaccine study and flu vaccine submissions, the overall revenue guidance for 2025 has been reduced, reflecting delays in vaccine deliveries.
Moreover, Anderson highlights that Moderna’s financial health remains heavily reliant on COVID-related revenues, which poses forecasting challenges. There is skepticism about the company’s ability to diversify its revenue streams with other programs like RSV and CMV vaccines. Additionally, political risks associated with the mRNA platform and COVID vaccines further contribute to the cautious outlook. These factors collectively underpin the decision to maintain a Sell rating on Moderna’s stock.
Anderson covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Merck & Company. According to TipRanks, Anderson has an average return of 9.1% and a 61.76% success rate on recommended stocks.
In another report released on July 17, J.P. Morgan also maintained a Sell rating on the stock with a $26.00 price target.